Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Treatment of Oligometastatic EGFR-Mutant Lung Cancer

2.

Veterans of the Navy have high lung cancer rates associated with asbestos use.

3.

In women with extremely dense breasts, elevated MRI enhancement can help identify cancer risk.

4.

FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

5.

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot